Track Ginkgo Bioworks Holdings Inc. Class A Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Ginkgo Bioworks Holdings Inc. Class A Common Stock DNA · Stock Open Ginkgo Bioworks Holdings Inc. Class A Common Stock in new tab

7.99 USD
EPS
-5.33
P/B
1.07
ROE
-59.94
Beta
1.77
Target Price
7.00 USD
Ginkgo Bioworks Holdings Inc. Class A Common Stock logo

Ginkgo Bioworks Holdings Inc. Class A Common Stock

🧾 Earnings Recap – Q2 2026

Shares plunged 9.3% following a steep 48% revenue decline and continued margin pressure, signaling investor disappointment with significant top-line deceleration and ongoing elevated losses despite cost-cutting efforts.

  • Q2 revenue dropped 48% year-over-year to $20 million, reflecting sharp deceleration in core business.
  • Adjusted EBITDA loss widened to $36 million from $25 million a year ago, indicating margin compression despite reduced operating expenses.
  • Net loss from continuing operations increased to $57 million from $53 million in Q2 2025.
  • Cash burn rose to $45 million in Q2, up from $38 million the prior year, despite restructuring and cost controls.
  • Guidance maintained for 2026 cash burn of $125 million to $150 million, showing cautious outlook without improvement in near-term profitability.
📅
Loading chart...
Key Metrics
Earnings dateNov. 5, 2026
EPS-5.33
Book Value6.60
Price to Book1.07
Debt/Equity96.15
% Insiders4.433%
Growth
Revenue Growth-0.49%
Estimates
Forward P/E-2.44
Forward EPS-2.90
Target Mean Price7.00

DCF Valuation

Tweak assumptions to recompute fair value for Ginkgo Bioworks Holdings Inc. Class A Common Stock (DNA)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Ginkgo Bioworks Holdings Inc. Class A Common Stock Logo Ginkgo Bioworks Holdings Inc. Class A Common Stock Analysis (DNA)

United States Health Care Official Website Stock

Is Ginkgo Bioworks Holdings Inc. Class A Common Stock a good investment? Ginkgo Bioworks Holdings Inc. Class A Common Stock (DNA) is currently trading at 7.99 USD. Market analysts have a consensus price target of 7.00 USD. This suggests the asset is currently trading above analyst expectations.

Earnings Schedule: Ginkgo Bioworks Holdings Inc. Class A Common Stock is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -2.90.

Investor FAQ

Does Ginkgo Bioworks Holdings Inc. Class A Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Ginkgo Bioworks Holdings Inc. Class A Common Stock?

Ginkgo Bioworks Holdings Inc. Class A Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -5.33.

Company Profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Exchange Ticker
ASE (United States) DNA
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Aug. 20, 2024 0.03
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion